BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
CANTON, Mass., May 02, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
